CareDx, Inc. — Q1 2024 Form 10-Q
Reporting period: Three months ended March 31, 2024. CareDx develops and commercializes transplant diagnostic testing, products, and patient and digital solutions.
Financial performance
| Metric | Q1 2024 | Q1 2023 | Change |
|---|---|---|---|
| Revenue | $72.0 million | $77.3 million | Down 7% |
| Testing services revenue | $53.8 million | $61.8 million | Down 13% |
| Product revenue | $8.6 million | $6.9 million | Up 25% |
| Patient and digital solutions revenue | $9.6 million | $8.6 million | Up 12% |
| Net loss | $16.7 million | $23.7 million | Improved $7.1 million |
| Operating cash flow | $(15.3) million | $0.7 million | Decreased $16.0 million |
- Direct costs of revenue were $25.9 million, producing an approximate gross margin of 64.0%, compared with 66.4% a year earlier. Operating loss was $19.3 million, versus $24.3 million.
- Research and development expense fell 23% to $18.7 million; sales and marketing fell 15% to $19.8 million; general and administrative expense fell 4% to $26.9 million. The filing attributes reductions to lower clinical-trial and personnel costs, among other items.
- At March 31, cash and cash equivalents were $93.3 million and marketable securities were $122.6 million, totaling approximately $215.9 million. The company reported no debt and an accumulated deficit of $695.5 million. Total assets were $452.4 million and total liabilities were $196.2 million.
- Cash, cash equivalents and restricted cash increased $11.1 million during the quarter, principally reflecting $27.7 million of net proceeds from marketable-security maturities and purchases; operating activities used $15.3 million.
Material changes and operating developments
- Year-over-year testing services revenue declined primarily because Medicare billing-article requirements reduced AlloMap and AlloSure Medicare volume. AlloSure Lung Medicare reimbursement partly offset the decline. Management also reported testing-services revenue up 15% and patient results up 6% versus Q4 2023, with approximately 42,000 results in Q1.
- Product growth was primarily driven by higher sales of commercial next-generation sequencing kits. Patient and digital solutions growth mainly reflected acquired HLA Data Systems and MediGO businesses.
- Medicare represented approximately 33% of total revenue in Q1 2024, down from 42% in Q1 2023. Separately, Medicare revenue for AlloMap Heart, AlloSure Kidney and AlloSure Heart represented 44% of testing-services revenue, as described in the risk disclosures.
- The company repurchased 55,500 shares for approximately $0.5 million; $21.4 million remained under its $50 million repurchase authorization at quarter-end. A universal shelf registration permits offerings of up to $250 million upon effectiveness.
Outlook, risks and contingencies
- Outlook: No specific quarterly or full-year revenue or earnings guidance is provided in the supplied filing text. Management expects existing cash and expected cash from operations and agreements to cover anticipated requirements for the next 12 months, while noting possible future financing needs. The company expects net losses for the next several years.
- Reimbursement: Medicare billing requirements have affected testing volume and revenue. Coverage, claim-submission rules and reimbursement rates remain important risks; the company reported a revised MolDX/Noridian billing article issued February 29, 2024.
- Litigation: A jury awarded Natera approximately $96.3 million in a patent case, and CareDx recorded that amount as a liability. CareDx is seeking judicial review and disputes ongoing infringement; Natera may seek injunctive relief. The patent expires in September 2026. Separately, CareDx’s appeal concerning its false-advertising case against Natera remains pending; the court upheld the verdict but did not uphold the jury’s monetary damages.
- Other legal matters: The DOJ investigation concerning kidney testing and phlebotomy practices remains unresolved. The SEC notified CareDx in September 2023 that it had concluded its investigation and did not intend to recommend enforcement. Securities class-action and derivative matters also remain pending or stayed, as described in the filing.
- Controls: Management concluded disclosure controls were ineffective as of March 31, 2024 because previously reported material weaknesses remained unremediated. These include IT general controls, purchase-order approval workflows, and COSO control-environment and monitoring deficiencies. Management is pursuing remediation.
- Other exposures: CareDx depends substantially on payer coverage and competes in transplant diagnostics. It reported foreign-currency exposure and no near-term plans for formal hedging. The Stanford license automatically terminated after the U.S. Supreme Court declined review; the company reported no outstanding Stanford obligation at quarter-end.
Important facts for investors to verify
- Whether Medicare billing requirements continue to constrain testing volume, collections, and revenue, and whether coverage policies change.
- The status and potential financial or operational consequences of the Natera patent verdict, including judicial review and any request for injunctive relief.
- Progress in remediating material weaknesses and whether controls become effective after testing over an adequate period.
- Operating cash burn relative to the $215.9 million of cash and marketable securities, and the assumptions supporting management’s 12-month liquidity assessment.
- Whether growth in product and digital businesses can offset testing-services weakness while CareDx continues to report losses.